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The rodent parvoviruses are known to be oncoselective, and lytically infect many transformed human
cells. Because current therapeutic regimens for metastatic melanoma have low response rates and have
little effect on improving survival, this disease is a prime candidate for novel approaches to therapy,
including oncolytic parvoviruses. Screening of low-passage, patient-derived melanoma cell lines for
multiplicity-dependent killing by a panel of ﬁve rodent parvoviruses identiﬁed LuIII as the most
melanoma-lytic. This property was mapped to the LuIII capsid gene, and an efﬁciently melanoma tropic
chimeric virus shown to undergo three types of interaction with primary human melanoma cells:
(1) complete lysis of cultures infected at very low multiplicities; (2) acute killing resulting from viral
protein synthesis and DNA replication, without concomitant expansion of the infection, due to failure to
export progeny virions efﬁciently; or (3) complete resistance that operates at an intracellular step
following virion uptake, but preceding viral transcription.
& 2013 Elsevier Inc. All rights reserved.Introduction
Malignant melanoma is a devastating, aggressive form of skin
cancer, derived from melanocytes, the pigment-producing cells in the
skin. It is responsible for roughly 75% of skin cancer deaths, despite
being one of the rarest forms of skin cancer, and its incidence has been
on the rise for the past 30 years (Chin et al., 2006). Life expectancy at
diagnosis is fewer than 12months with current therapies offering little
improvements to long-term survival (Hocker et al., 2008). Dacarba-
zine, an alkylating agent, has been the standard treatment for
melanoma since the 1970s (Wolchok, 2012). In 2010, the addition of
the immune-modulating anti-CTLA4monoclonal antibody ipilimumab
extended overall survival from 9 to 11 months following diagnosis
(Robert et al., 2011). More recently, the FDA approved vemurafenib, a
small molecule BRAF kinase inhibitor, speciﬁcally for patients bearing
the V600E mutation of BRAF (present in 40–60% of spontaneous
cases). In this population, the drug increases median survival to 15
months (Ravnan and Matalka, 2012). The limited efﬁcacy of these
cutting-edge treatments indicates that this malignancy represents a
prime candidate for novel approaches to therapy.
Some viruses possess the unique ability to target and destroy
cancer cells while having little to no effect on the untransformedll rights reserved.
ry Medicine, Yale University
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sall).parent tissue (Donahue et al., 2002). Therapy with such “oncolytic
viruses” offers additional desirable features, such as the ability to
locally amplify their dose at the site of the tumor and to provoke an
immune response to antigens expressed by dying tumor cells, all
while leaving healthy tissues unharmed (Prestwich et al., 2008).
Rodent parvoviruses are inherently oncoselective and oncolytic in
many human tumor cell lines, and importantly have the added
advantage of being non-pathogenic in humans (Dupont, 2003).
Autonomously replicating parvoviruses belonging to the genus Parvo-
virus, such as Minute Virus of Mice, MVM, are small, single-stranded
DNAviruses with a linear genome ∼5 kb in length (Tijssen et al., 2011).
Following binding to a currently uncharacterized receptor, and uptake
via receptor-mediated endocytosis, the MVM virion trafﬁcs to the
nucleus, where a host cell DNA polymerase, most likely pol δ, converts
the single-stranded genome into a double-stranded form that is active
as a transcription template (Cotmore and Tattersall, 2007). Host
replicative DNA polymerases, however, are only expressed during
the S-phase of the cell cycle, making parvoviruses naturally S-phase
dependent, and transcriptionally active only in dividing cells. The
completed template contains two promoters, P4 and P38. The initiat-
ing P4 promoter drives the expression of two non-structural proteins,
NS1 and NS2. NS1 has a variety of functions in the virus lifecycle,
including regulation of gene expression, DNA replication and packa-
ging, and induction of cell death (Cotmore and Tattersall, 2013). The
function of NS2 is less well understood, though, for MVM, it is required
in murine cell infection for efﬁcient DNA replication and capsid
assembly. However, NS2 expression is expendable in transformed
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the host cell (Choi et al., 2005; Cotmore et al., 1997; Eichwald et al.,
2002; Miller and Pintel, 2002; Naeger et al., 1993). NS1 also transacti-
vates the P38 promoter, which drives expression of the two capsid
genes, VP1 and VP2. These proteins assemble in a ∼1:5 ratio to form
empty capsids, which then package a single of copy of the viral
genome, before being released from the cell by an active process prior
to cell death, or as a result of cell lysis (Maroto et al., 2004). Previous
studies mapping tropism to viral genes demonstrated that the capsid
protein plays a major role in determining host range. Two strains of
the same parvovirus serotype, MVMp and MVMi, infect a distinct set
of host cells, and each is restricted in the other virus′ target cell.
However, the lymphotropic MVMi strain can acquire wild type levels
of infection in normally restrictive ﬁbroblasts with only two amino
acid changes in the capsid protein (Cotmore and Tattersall, 2007).
Further, the capsid appears to determine cell tropism not at the level
of binding to a target cells, but at a post-entry step (Paglino and
Tattersall, 2011).
While much effort has gone towards determining the viral
component of host tissue tropism, less effort has been expended
on exploring the differences in susceptibility to a single parvovirus
serotype of human tumors of the same tissue type. Parvoviruses and
parvoviral vectors have been shown to target a variety of human
tumor types, demonstrating increased ﬁtness and cytotoxicity in
transformed cells as compared to their normal counterparts (Cornelis
et al., 1990; Dupont et al., 2000). Glioma, another aggressive and
invariably fatal malignancy has been a target of extensive study,
including parvovirus infection of rodent models, established human
tumor lines, as well as low-passage patient samples (Wollmann et al.,
2012). Furthermore, a Phase I clinical trial of H1 parvovirus therapy
of glioblastoma multiforme is currently underway in Germany
(Geletneky et al., 2010). To date, the study of parvovirus oncolysis
of melanoma has been conducted with transplantable mouse modelsFig. 1. Identiﬁcation of the most potent parvovirus for infection and killing of stepw
Parvovirus, based on the protein sequences of the viral coat protein, VP2, and was kindly
aligned using a modiﬁcation of the Needleman–Wunsch local alignment method as imple
inference with a Yule model of speciation and an exponential relaxed molecular clock. T
parvoviruses, indicated by the asterisks, that cluster within the rodent virus subgroup (d
and added to sub-conﬂuent Mel-STR cells (panel B) or pMel-TCP-BRAF cells (panel C), as d
cells. Clear and partially clear wells indicate infection and killing of the melanoma cells(El Bakkouri et al., 2005; Lang et al., 2006; Raykov et al., 2005;
Wetzel et al., 2007), and long-established humanmelanoma cell lines
(Dupont et al., 2000). However, no comprehensive survey of a broad
range of rodent parvovirus serotypes against freshly isolated human
melanoma cells has been undertaken to date. In the current study we
screened a panel of seven antigenically distinct rodent parvoviruses
to identify the best candidate virus for targeting malignant mela-
noma, and further characterized the ability of the leading candidate
virus to infect and kill a broad range of low-passage, patient-derived
melanoma cell lines.Results
A subgroup of rodent parvoviruses can kill stepwise-transformed
human melanocytes
To identify the most potent oncolytic parvovirus for malignant
melanoma, we initially screened a panel of seven antigenically distinct
rodent parvovirus serotypes for the ability to kill two stepwise-
transformed melanocyte lines. The viruses screened include the
murine viruses Minute Virus of Mice (MVMp, the prototype strain)
and mouse parvovirus (MPV1), the rat parvoviruses H1, H3 (also
known as Kilham Rat Virus), and rat parvovirus (RPV1), and two
serotypes of unknown hosts originally isolated from human tumor
samples, LuIII and TVX (Fig. 1A) (Hallauer et al., 1972). Stepwise-
transformed models were chosen for the initial screen because they
contain a minimal number of genetic mutations needed for transfor-
mation, and therefore do not also exhibit the numerous collateral
mutations that frequently occur as a result of genetic instability in
spontaneous tumors, but contribute no advantage to ﬁtness (Chin
et al., 2012). Such minimally mutated models should generalize for
parvovirus infection across many spontaneous clinical melanomas,ise-transformed melanoma models. Panel A: the phylogenetic tree of the genus
provided by Susan Cotmore, Derek Gatherer and Andrew Davison. Sequences were
mented in MOE-Align (http://www.chemcomp.com), and calculated using Bayesian
he melanoma killing screens were performed with the seven antigenically distinct
ashed bracket). Serial 5-fold dilutions, from 5000 vge/cell, were made of each virus,
escribed in the Methods section. At 6 days post-infection wells were stained for live
by the indicated virus.
Fig. 2. Patient-derived melanoma cell lines respond to infection with three distinct
outcomes. One representative is shown from each category of killing assay outcome
—panel A, sensitive (n¼2); panel B, intermediate (n¼8); and panel C, resistant
(n¼3); the 13 patient-derived melanoma lines screened for parvovirus killing.
Sub-conﬂuent cells were infected with 5-fold serial dilutions of each virus and
stained 6 days post-infection, as described in the Methods section.
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of any one clinical sample should be avoided. Mel-STR cells (Gupta
et al., 2005) have been immortalized with the catalytic subunit of
telomerase, then transformed with the SV40 viral oncogenes large
T antigen (inactivation of p53 and Rb-family proteins) and small t
antigen (PP2A modulation), plus oncogenic RAS (Ras G12V). Due to
the fact that the SV40 T antigens are themselves multifunctional viral
replication proteins with oncogenic properties, we were concerned
that they might also provide parvovirus helper functions beyond those
necessary for cellular transformation. Therefore, we also tested a
second stepwise-transformed cell line, pMel-TCP-BRAF (Garraway
et al., 2005). This model is transformed without viral oncogenes,
instead employing telomerase, constitutively active CDK4 (CDK4R24C),
a dominant negative form of p53, and activated BRAF (BRAFV600E). The
V600E mutation of BRAF mirrors the human disease, as this point
mutation is found in about 60% of clinical melanomas (Davies et al.,
2002). To compare the oncolytic potency of each member of the panel
of viruses, we performed a multi-well killing assay, in which rapidly
dividing target cells were infected with a series of 5-fold dilutions of
each of the seven virus serotypes, beginning at an MOI of 5000 vge/
cell. Each virus was allowed to infect, kill, and spread through the
melanoma culture over 6 days, before staining the remaining live cells
(Fig. 1B and C). Five of the seven parvovirus, MVM, H3, TVX, MPV, and
RPV, displayed no killing in either of the two stepwise-transformed
melanoma models, even at the highest MOI used. However, both
tumor models were productively infected by the parvoviruses H1 and
LuIII, as demonstrated by wells fully or partially cleared of live
melanoma cells. In both cases, H1 efﬁciently kills the culture from
an input of 1000 vge/cell, and shows evidence of killing at the 200 vge/
cell dilution demonstrated by incomplete growth of the melanoma
monolayer. LuIII, however, effectively killed the entire melanoma
culture at an input of 200 vge/cell, an input that initially leads to
infection of about 5% of susceptible patient-derived melanoma cells, as
discussed below. This demonstrates the ability of LuIII not just to infect
melanoma, but also to replicate and spread through the culture, and
identiﬁes this virus as the optimal candidate for melanoma oncolysis
in these two model systems.
Primary human melanomas vary in their responses to parvovirus
infection
We next screened a subset of ﬁve of these viruses, MVMp, H1, LuIII,
H3, and TVX, using this killing assay, across a panel of 13 patient-
derived, very low-passage melanoma samples. Fig. 2A–C, shows
representative assays from this screen, chosen to illustrate the three
types of outcome observed, as discussed below. As observed with the
stepwise-transformed cells, MVMp and H3 demonstrated no killing
ability in any of the patient-derived cell lines. We concluded from this
screen that LuIII, and less potently H1, are the most efﬁcient at
infecting freshly isolated human melanoma cells, as predicted by the
two melanoma models; however, the individual outcomes observed
across the entire panel of patient-derived cultures were more varied.
The results of the screen divided the cell lines into three distinct
groups. Three cell lines: YUSIT1, YURIF, and WW165 appeared to be
completely resistant to all ﬁve serotypes of parvovirus, growing to
conﬂuent monolayers even after exposure to the highest MOI. Eight
cell lines, YUSAC-2, YUMAC, YUDOSO, YUKSI, YUKIM, YUROL, YUPLA,
and YUHEF, showed evidence of infection and killing by both H1 and
LuIII at only the highest virus input, with a spotty, incomplete recovery
of the monolayer after 6 days of infection. Finally, two cell lines, 501-
Mel and MNT1, mirrored the stepwise models in their sensitivity to
both H1 and LuIII viruses. H1 showed complete killing of the culture
down to a starting input of 200 vge/cell, and evidence of killing at an
input as low as 8 vge/cell. LuIII demonstrated complete killing starting
from only 40 vge/cell, and disruption of the resulting monolayer at
both 8 and 1.6 input genomes per cell. These data demonstrated thatthe basic pattern of H1 and LuIII infectability seen in the stepwise
melanoma models was reproduced in patient-derived cultures, with
variability in the potency of the viruses in different cell lines, and
conﬁrmed that LuIII represents the best candidate, among the viruses
tested, for parvoviral oncolysis of melanoma. Interestingly, one addi-
tional parvovirus serotype, TVX, a previously uncharacterized virus,
demonstrated potency in the two most infectable cell lines, 501-Mel
and MNT1, beyond that of either H1 or LuIII. However, TVX did not
demonstrate any killing ability in either of the stepwise-transformed
melanoma model (Fig. 1B and C), or in the other 11 clinical samples.
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infection of the patient-derived cell lines, we wished to further
explore differences in the LuIII lifecycle in these three groups. This
approach was constrained by the fact that the majority of tools we
have developed identify components of the prototype strain MVMp, a
serotype unable to infect human melanoma cells. However, previous
studies from our laboratory, of MVMp-resistant transformed human
ﬁbroblasts, showed that the LuIII VP2 capsid gene was sufﬁcient to
confer efﬁcient infectivity on MVMp for this cell type (Paglino and
Tattersall, 2011). We therefore compared the chimeric virus LuCap, in
which the MVMp VP2 capsid gene has been replaced with that of
LuIII (Fig. 3A), with both of its parents, using the 6-day killing assay in
a representative clinical melanoma cell line from each sensitivity
group. Fig. 3B shows that this virus does indeed demonstrate tropism
for human melanoma cells, and kills these cells with nearly the same
efﬁciency as the parent LuIII virus, allowing the study of parvovirus
infection and killing of melanoma in the context of the prototype
MVMp backbone. The further experimental analyses reported here
were performed exclusively with LuCap.The majority of melanoma lines support initiation of infection
Having identiﬁed LuCap as an optimal candidate for melanoma
oncolysis, we focused on infection of the panel of patient-derived
lines with this chimeric virus. First, the ability of LuCap to establish
infection in 24 h was examined by measuring the expression of
the early non-structural protein NS1 using ﬂow cytometry. Analy-
sis of the 13 cell lines revealed that a majority support initiation of
infection by LuCap, as shown, in Fig. 4A, by a dose-responsive
increase in NS1-positive cells with increasing input MOIs. For 10 of
the cell lines between 12% and 70% of the cells became positive for
NS1 when infected with 5000 vge/cell. The three cell lines, YUSIT1,
YURIF, and WW165, that were found to be resistant to all the
parvoviruses used in the initial screen also displayed essentiallyFig. 3. The LuIII capsid gene confers melanoma tropism to MVMp. Panel A
diagrams the chimeric virus LuCap, showing its MVMp genome backbone and
the dispositions of both viral promoters, and the LuIII VP2 capsid gene replacing
that of MVM. Panel B shows killing assays of representative patient-derived
melanoma cell lines with the parent viruses MVMp and LuIII, and the LuCap
chimera. Sub-conﬂuent cells were infected and stained as described in the Methods
section.
Fig. 4. Infection initiation and expansion of LuCap infection in patient-derived
melanoma cell lines. Panel A shows a histogram representing the percent of cells
expressing NS1 at 24 hpi, as measured by ﬂow cytometry. The 13 cells lines,
indicated at the bottom, were infected with LuCap virus at increasing MOIs, in
5-fold steps from 8 to 5000 vge/cell, as indicated by the shading intensity of the
bars. Panel B shows a graphical representation of the percent of cells expressing
NS1 as a function of time after infection, for cell lines initially infected at a single
MOI of 100 vge/cell, collected at 24 h (white bars), 48 h (gray bars), and 72 h (black
bars), and analyzed by ﬂow cytometry.complete resistance to the induction of NS1 expression by LuCap,
even at the highest MOI used (Fig. 4A).
Next we measured the ability of LuCap to replicate productively
and expand through dividing melanoma cultures over 72 h, following
infection at an initially low MOI (100 vge/cell) (Fig. 4B). Again, the cell
lines fell into two groups: those that support a productive, expanding
infection, and those that do not. The 501-Mel and MNT1 support
expansion, as the percentage of NS1-positive cells in these two lines
increased from 2% and 6% at 24 h, to 22% and 24% at 72 h, respectively.
This indicates that infected cells produce progeny virions that spread
to infect additional cells in the culture, at a rate faster than the
remaining uninfected cells can repopulate the culture. The remaining
11 cell lines failed to support a productive infection, showing no
Fig. 5. Virion binding to, and occlusion by, patient-derived melanoma cells. Cells
were infected for 4 h with LuCap virions, and incubated for a further 2 h to allow
for recycling of virus from the cell. For the pre-cleaved samples (white bars), cells
were incubated prior to infection with neuraminidase to prevent virus binding. For
the occluded samples (light gray bars), cells were incubated for the ﬁnal 2 h in
neuraminidase-supplemented medium to cleave surface-bound virions, while for
the “bound and occluded” samples (dark gray bars), neuraminidase was omitted in
order to measure the total cell-associated virus. Cells were lysed at 6 hpi, and
lysates were analyzed for virus genomes by qPCR. The percent uptake is calculated
versus qPCR of the total input virus added to an uninfected lysate.
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infection (hpi).
By superimposing the results for infection initiation and expansion
in these cell lines, we clearly identify three overall infection outcomes,
partitioning the cell lines into three subgroups: resistant (YUSIT1,
YURIF, WW165), intermediate (YUSAC-2, YUMAC, YUDOSO, YUKSI,
YUKIM, YUROL, YUPLA, YUHEF,) and sensitive (501-Mel, MNT1)
(Fig. 4). The three cell lines in the resistant subgroup are not
permissive to infection, or even the establishment of NS1 protein
expression, in the initial infection. Members of the intermediate
subgroup are permissive to infection, supporting at least the early
stages of the viral lifecycle, including early gene expression; however,
the lack of expansion suggests a late block in the lifecycle. Finally, the
two cell lines in the sensitive subgroup are efﬁciently infected in the
ﬁrst round, and support a productive infectionwith expansion through
the culture, as illustrated by the increase in the NS1-positive cells over
time, and complete the destruction of the monolayer even at low
input MOIs.
Human melanoma cell lines bind and internalize LuCap virions
regardless of their infectability
Two representative cell lines were selected from each of these
three subgroups for further analysis: sensitive 501-Mel and MNT1,
intermediate YUSAC-2 and YUMAC, and resistant YURIF and WW165.
To determine the step in the viral lifecycle at which infection is
blocked in resistant cell lines, we ﬁrst examined their ability to bind
and internalize virus particles. Although the receptor(s) for MVM and
LuIII remain uncharacterized, they contain an essential terminal sialic
acid residue, as judged by the ability of neuraminidase treatment to
reverse cell surface binding of either virus, and this property can be
used to measure the kinetics and extent of virion binding and entry.
Cells were infected for 4 h with LuCap virus, and then incubated for an
additional 2 h either with neuraminidase, in order to measure virus
particles that had been internalized, or without neuraminidase to
assess total cell-associated virus. As a control, one sample from each
cell line was treated with neuraminidase prior to infection, to conﬁrm
that the virus requires surface sialic acid moieties for entry into each of
the cell lines. Following infection, parvoviral genomes in the cell
lysates were measured by qPCR. In all cases, neuraminidase pre-
treatment effectively blocked virus binding and uptake (Fig. 5). Each of
the six cell lines showed an increase in qPCR signal following infection,
indicating that all cell lines are capable of binding the virus. Notably, all
cell lines, including the two resistant cell types retained most of this
signal following neuraminidase cleavage of bound virus, demonstrat-
ing their ability to also internalize virus. Although the cell lines differed
somewhat in the measured amount of internalized virus, there was no
correlation between the infectability of subgroups and the amount of
virus they internalized. Indeed, LuCap virions were able to bind to, and
successfully enter, the resistant cells YURIF and WW165 to levels
equivalent to, or even exceeding, those seen for permissive cells,
indicating that the infection of these resistant cells is blocked at a post-
uptake step.
Resistant cell lines are blocked for infection prior to viral gene
transcription
Following internalization, trafﬁcking of virus into the nucleus, and
entry of the host cell into S-phase, the single-stranded viral genome
is uncoated and converted to duplex DNA by host DNA polymerase,
creating a transcription template, initially for mRNAs driven by the
P4 promoter. We next looked for evidence of transcription of the
earliest expressed genes, NS1 and NS2, in resistant cells infected with
LuCap, since the failure to detect NS1 protein expression in resistant
cells in the initiation assay does not rule out a post-transcriptional
block to gene expression. To measure the amount of viral genetranscription from the P4 promoter, we measured the levels of R1
and R2 transcripts at 24 h after infection, using RT qPCR and a primer
strategy indicated in Fig. 6A. As shown in Fig. 6B, each of the sensitive
and intermediate cell lines transcribe both NS1 and NS2 genes, but
the resistant cells did not support detectable transcription of either
NS1 or NS2 genes, indicating that the competent P4 transcription
complexes fail to form in these cells.
Since the intermediate cell lines expressed P4 transcripts abun-
dantly, the next step in identifying the block to infection in these cells
was to analyze the translation of viral transcripts, particularly those of
the capsid genes VP1 and VP2, whose expression is dependent upon
NS1 transactivation of the P38 promoter. For this, we infected all six
representative cell types at a high MOI, and analyzed viral protein
expression at 24 hpi by western blot. Sensitive and intermediate cells
all expressed signiﬁcant levels of NS1, and the capsid gene products
VP1 and VP2 (Fig. 7). The ancillary protein NS2, which, as discussed
above, has been found to be non-essential for the infection of several
transformed human cells, was expressed at lower, more variable
levels, reﬂecting the lower levels of the R2 transcript class that encodes
them observed in Fig. 6B. Importantly, LuCap infection of intermediate
cell lines led to signiﬁcant accumulation of the viral capsid gene
products, indicating that the block causing their failure to support a
second round of infection operates after capsid gene expression.
Intermediate cell lines support viral DNA replication
In order for progeny viral particles to be generated, the viral
genome must ﬁrst be ampliﬁed as duplex DNA by rolling hairpin
replication, nicked by NS1, and 5 kb single-stranded viral genomes
displaced from these duplexes for packaging (Cotmore and Tattersall,
2005b). To measure DNA synthesis, the cells were infected under
single-round conditions, intracellular DNA isolated at 6, 24 and 48 h,
and analyzed by a qPCR assay that detects a viral DNA sequencewithin
the NS1 gene (Fig. 8A). These results indicate that both sensitive and
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LuCap begins DNA replication rapidly, within 24 h, while MNT1 and
YUSAC-2 lag behind, continuing to increase the rate of replication
between 24 and 48 h. The intermediate cell line YUMAC alsoFig. 6. Measurement of P4 promoter activity in representative melanoma cells.
Panel A depicts the arrangement of the spliced transcripts and the primers used to
detect them. For panel B, two representative cell lines from the three infectability
subgroups were infected at high multiplicity and collected at 24 h for RNA isolation
and cDNA synthesis. Viral R1 (NS1-encoding—white bars) and R2 (NS2-encoding—
gray bars) transcripts were measured by SYBR Green qPCR, as described in the
Methods section. Copy number was calculated by comparison to standard curves of
NS1 and NS2 cDNA sequences.
Fig. 7. Analysis of viral gene expression in representative melanoma cell infections.
Six cell lines representing the three infectability subgroups were analyzed by
western blotting following 24 h of infection at high multiplicity. Blots were probed
for the products of the non-structural genes NS1 and NS2, and the capsid genes VP1
and VP2, using speciﬁc antibodies, as described in the Methods section.
Fig. 8. Viral DNA replication in representative melanoma cell infections. Cells were
infected at high multiplicity under single-cycle conditions. Intracellular DNA was
isolated from cells at 6, 24 and 48 hpi. For panel A, viral DNA was measured by
qPCR for all six cell lines, with copies quantiﬁed by comparison to a standard curve
of LuCap plasmid DNA. For panel B, 10 kb dimer (dRF) and 5 kb monomer (mRF)
replicative forms of viral DNA, and single-stranded progeny viral genomes (ss),
isolated from infected sensitive and intermediate cells, were separated by size in a
neutral gel and analyzed by Southern blot, as described in the Methods section.demonstrates replication, though at a slower rate than the others.
Finally, the two resistant cell lines failed to replicate viral DNA, as was
expected in the absence of NS1 expression, the viral protein critical for
genome replication. These cell lines were not, therefore, included in
subsequent analyses of the viral replication cycle. The qPCR approach
to measuring genome ampliﬁcation, however, does not elucidate the
state of the replicating DNA, since 5- and 10-kb duplex replicative
forms, single-stranded, packaging-competent genomes, and hybrid
replicative intermediates are all detected as a single signal. To detect
these different replicative forms and to determine whether single-
stranded genomes were being released, we separated the DNA by size
on a neutral gel, and detected viral DNA by Southern blot (Fig. 8B).
These data demonstrate that both intermediate cell lines successfully
replicate viral DNA, and accumulate intracellular single-stranded 5 kb
genomes, though at a signiﬁcantly lower rate than the sensitive 501-
Mel cell line. Interestingly, the sensitive cell line MNT1, which supports
both initiation and expansion of LuCap at slightly higher levels than
Fig. 9. Capsid assembly in representative melanoma cell lines. Sensitive and
intermediate cell line representatives were infected at high multiplicity under
single-cycle conditions. Cell lysates were prepared at 48 h and centrifuged through
an iodixanol step gradient to separate viral particles by density, as described in the
Methods section. Fractions are numbered from the bottom of the gradient, and the
banding positions of full virions (V) and empty capsids (C) are indicated. In panel A,
each fraction was analyzed by western blot for capsid genes VP1 and VP2, and in
panel B, hemagglutination (HA) assays were performed on each fraction for the two
intermediate cell lines, YUSAC-2 () and YUMAC (■), and compared to those for the
sensitive cell line 501-Mel ( ). Titers are expressed as a percent of the total HA
recovered from each gradient.
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effectively than 501-Mel, in fact demonstrating the same level of
replication as the intermediate cell line YUSAC-2, a cell line which fails
to support viral expansion. Therefore, the decreased rate of DNA
replication demonstrated by the intermediate cell lines does not alone
account for the late block to infection, since the decreased rate of
replication in MNT1 does not hinder rapid expansion of LuCap
infection in cultures of this cell line.
Intermediate cell lines assemble viral capsids correctly
Capsid protein analysis by western blot does not give informa-
tion about the ability of cells to assemble the capsid protein
monomers into three-dimensional capsids. In order to assess
capsid assembly, we infected cells for 48 h at a high MOI, and
separated cell lysates by density on iodixanol gradients, and
analyzed fractions from this gradient for the presence of capsid
proteins by western blot, as shown in Fig. 9A. In the fractionation
of sensitive cell extracts, the bulk of viral capsid protein forms a
peak centered on fraction 7, in the position of assembled, but
empty, particles. Full particles, containing the viral genome, would
be expected to band between fractions 3 and 4, but have not
accumulated levels detectable by western blot by this point in
infection, at least as intracellular particles. The intermediate cell
lines YUSAC-2 and YUMAC appear to assemble capsids nearly as
efﬁciently as the sensitive lines 501-Mel and MNT1, showing a
similar pattern, with capsid proteins banding in the empty particle
region of the gradient. For both sensitive and intermediate cell
infections, the capsid distribution in these gradients coincides
with the peak of hemagglutination activity, which is a property of
assembled capsids. Thus, the failure of the intermediate cells to
support multiple rounds of infection does not result from a failure
to assemble capsids correctly, and must instead be based on
deﬁcient packaging or release of progeny virus from infected cells.
Intermediate cell lines fail to export progeny rapidly
Since intermediate cell lines generate single-stranded genomes
during viral DNA replication and assemble VP1 and VP2 proteins
into capsids, the next step was to determine whether these
genomes were being packaged into the assembled capsids. To this
end, we analyzed the fractions in the region of the iodixanol
gradients where packaged virions band for viral DNA. To deﬁni-
tively determine whether the viral DNAwas packaged into capsids,
any uncoated DNA was digested with micrococcal nuclease.
Additionally, to measure the amount of progeny virions released
into the medium over the 48 h infection, we digested any un-
encapsidated DNA in the medium with micrococcal nuclease, and
concentrated the sample prior to alkaline gel electrophoresis and
Southern blot analysis (Fig. 10A). Intracellular encapsidated viral
DNA was present in all four cell lines, and peaked at fraction 3,
indicating the ability of both intermediate cell lines to package
progeny virions. Surprisingly, the amount of full particles in the
sensitive cell line MNT1 was far lower than that of the sensitive
line 501-Mel, and further was signiﬁcantly below the amount of
packaged intracellular progeny found in the intermediate cell line
YUSAC-2. However, the analysis of extracellular virus demon-
strates that both sensitive cell lines effectively export packaged
progeny virions out into the medium, as that is where the vast
majority of signal is found. This explains both the low levels of
intracellular single-stranded progeny DNA seen in Fig. 8B, and the
absence of capsid proteins or hemagglutinin detectable at the
position where full virions would band in the gradients shown in
Fig. 9. The medium from both intermediate cell lines also con-
tained progeny virions, but in much lower abundance compared to
either sensitive cell line. Comparison of the quantiﬁed bandsrevealed that sensitive cell lines export 25–30 times more progeny
virions into the medium than they contain intracellularly, whereas,
for the intermediate cell lines, this ratio is only 6–7 (Fig. 10B).
Thus, the early progeny release from the sensitive cell lines likely
represents the key factor allowing for rapid expansion through the
culture, at a rate sufﬁcient to overwhelm even a rapidly growing
cell population.
Permissive cell lines die as a consequence of infection
While it is clear that a majority of the melanoma lines are
infectable with the LuCap virus, it was important to determine the
outcome of infection, particularly for the intermediate cell lines that
are permissive to LuCap virus, but fail to amplify the infection. To
study this, cells infected under single-round conditions were harvested
at 24, 48, and 72 h and stained for dead or dying cells, as described in
theMethods section. For this, infectedmonolayers were stained with a
cell-impermeant dye which, while ﬂuorescently staining surface
Fig. 10. Progeny genome packaging in representative melanoma cell infections.
Panel A: lysates of cells infected for 48 h were fractionated by density as described
in Fig. 9. Samples from indicated fractions were treated with micrococcal nuclease
to cleave un-encapsidated DNA. Protected, packaged 5 kb DNA was then electro-
phoresed on an alkaline gel, and analyzed by Southern blot. The intracellular
fractions represent 60% of the total volume of each fraction, whereas released
samples represent micrococcal nuclease-protected virus genomes in concentrated
extracellular medium, representing 10% of the total medium volume. Panel B:
quantiﬁed bands were corrected for their representative volumes, and resulting
ratios represent the amount of packaged DNA in the medium compared to the
amount of packaged DNA in fraction 3, for each cell line.
Fig. 11. Analysis of the fate of representative melanoma cells following infection.
Sensitive and intermediate representative cell lines were infected with 1000 vge/
cell, under single-cycle conditions. Cells were collected at 24 hpi (white bars),
48 hpi (light gray bars) and 72 hpi (dark gray bars), and stained for plasma
membrane integrity and NS1 expression, as described in the Methods section.
Panel A shows the percent of cells infected (NS1-positive) at each time point. Panels
B and C show the percent of NS1-positive and NS1-negative cells, respectively, that
are also positive for the high intensity staining that indicates loss of plasma
membrane integrity.
E.M. Vollmers, P. Tattersall / Virology 446 (2013) 37–4844moieties on intact cells, stains those that have lost plasma membrane
integrity with one to two orders of magnitude greater intensity. After
removal of the dye and washing, the cells were ﬁxed, permeabilized
and co-stained with antibody to viral NS1 to identify infected cells,
then analyzed by ﬂow cytometry. Fig. 11A shows the percent of cells
positive for NS1 at the three time points. In each case, the percent
infected decreased over time, presumably due to neuraminidase-
mediated inhibition of second round infection and the continued
division of uninfected cells. To determine the fates speciﬁcally of
infected cells, we gated on NS1-positive cells and analyzed the percent
positive for the intense ﬂuorescence marker of cell death. As shown in
Fig. 11B, for both sensitive and intermediate cell lines the percent of
dead and dying infected cells increased over the course of the
experiment, indicating that the infection was inducing cell death
irrespective of whether the infection was productive or restrictive.
To control for the normal occurrence of cell death in culture, we also
measured the percent of dead cells after gating on the uninfectedpopulation. Fig. 11C shows that this percentage did not increase over
time, conﬁrming that the dying and dead cells in each of the cultures
were losing their plasma membrane integrity as a direct result of virus
infection, independent of their ability to sustain an expanding
infection.Discussion
In this study, we identiﬁed LuIII as the parvovirus with the
greatest potential for infecting and killing the majority of primary
human melanomas tested, with the LuIII VP2 capsid gene being
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virus MVMp. LuCap was able to initiate infection, demonstrated by
the expression of NS1, in 10 of 13 very low-passage, patient-
derived melanoma cell lines.
A minority of human melanomas are resistant to rodent parvovirus
infection
Three of the tested melanoma lines failed to support initiation
of infection, blocking the virus at an early step, prior to gene
expression, but after uptake into the host cell. Between these two
stages, the virus must escape the endosome, trafﬁc to and enter
the nucleus, and release its single-stranded genome, which must
be converted to a double-stranded form, by host DNA polymerase,
and establish itself as a competent transcription template. Infec-
tion may be blocked at any one of these steps in resistant cells;
however, the successful trafﬁcking of a virus to the nucleus
appears to be a rare event even in permissive cells, demonstrated
by high particle-to-infectivity ratios, variously estimated at 300:1
for MVMp, 1000:1 for CPV, and 500–1000:1 for H1 (Cotmore and
Tattersall, 2007; Paradiso, 1981), a fact that greatly complicates
effective analysis of these early steps of the virus lifecycle. Thus, at
this time, the block to infection in resistant cell lines can only be
identiﬁed as occurring at a post-uptake, pre-transcriptional step.
Similar early, post-entry blocks have been reported frequently for
parvovirus infections, and, in some cases, have been found to map
to the capsid gene (Bergeron et al., 1996; Bloom et al., 1993;
Paglino and Burnett, 2007; Paglino and Tattersall, 2011; Parrish
and Carmichael, 1986). Capsid-mediated blocks can often be
overcome by transfection of the infectious clone, resulting in the
progression of the virus lifecycle (Gardiner and Tattersall, 1988;
Previsani et al., 1997). However, the resistant melanoma cell lines
described in the current study proved exceedingly difﬁcult to
transfect, failing to express a control gene under a variety of
transfection conditions, so we cannot yet determine whether
bypassing the early, post-uptake role of the virus capsid would
result in gene expression and DNA replication in these cell lines.
If this were found to be the case for these resistant melanomas,
it would indicate that an alternative capsid might be employed to
confer viral infectivity against the resistant cells.
Most human melanomas are killed by rodent parvovirus infection
Of the 10 cell lines that supported infection, only two efﬁciently
supported multiple cycles, allowing the infection to spread over
time. The remaining eight intermediate cell lines failed to generate
and export sufﬁcient progeny to sustain the infection, but never-
theless died as a result of the initial infectious event. Investigation
of similar blocks to parvovirus infection in other systems points to
a role for the non-structural genes in determining successful
oncotropism at this later stage of infection (Choi et al., 2005;
Eichwald et al., 2002; Rubio et al., 2001). For instance, MVMi
infection of human astrocytic tumors uncovered two types of late
blocks. Infection of U87 cells failed to proceed to viral DNA
replication, despite conversion of the genome to a double-
stranded form, and robust viral protein expression. On the other
hand, infection of U373 cells was restricted by weak production
and release of infectious progeny, despite efﬁcient protein expres-
sion and DNA replication. The latter block was overcome by
exchanging a portion of the MVMi non-structural gene sequence
with that from MVMp, which is not restricted for growth in these
cells (Rubio et al., 2001). Additionally, when MVMi DNA was
transfected into murine ﬁbroblasts, in order to bypass its capsid-
mediated restriction in this cell type, the virus failed to produce
progeny genomes efﬁciently. However, changing a single, non-
coding nucleotide within the major intron splice acceptor site tothat present in MVMp results in an increase in the relative levels of
R2 transcripts, which encode NS2, and leads to robust progeny
genome production and packaging (Choi et al., 2005). Thus the
requirements for relative amounts of the NS splice variants can
play a major role in late stages of the virus lifecycle, can vary from
cell to cell, and between host species. While the requirement for
NS2 in murine cells appears to be absolute, expression of this
ancillary protein appears to be dispensable for efﬁcient infection of
many transformed human cells (Cotmore et al., 1997; Naeger et al.,
1993, 1990), suggesting that a dysfunction of NS1, rather than NS2,
may be involved in the late block in the human melanoma cells
studied here. If NS1 is indeed involved in the late block, it stands to
reason that an appropriate chimeric virus, encoding both mela-
noma tropic capsid and NS genes, could confer the ability to
efﬁciently export packaged progeny from infected cells, to aid in
rapid expansion through the culture, although recent studies
suggest that this may not be an important factor in cancer
virotherapy.
Parvoviral oncolysis might require cell killing, rather than expansion
of infection
While an expanding infection would be optimal for infecting the
bulk of cells in a tumor, in practice it may not be necessary for
therapeutic efﬁcacy in vivo. The majority of melanoma lines supported
at least initiation of infection, and regardless of the ability to produce
progeny for additional rounds, infection invariably ended in the death
of the infected cell. This ﬁnding is critical in that it indicates that even
cancers that support only a single round of virus-induced cell death
might still be susceptible to the immunological sequelae of parvovirus
infection. Some chemotherapeutic agents (e.g. anthracyclines, oxipla-
tin, and oxidizing radiation) owe a signiﬁcant portion of their out-
standing efﬁcacy to the fact that cancer cells treated with them die by
a process described as immunogenic cell death, priming the adaptive
immune system for cytotoxic T cell-mediated destruction of residual
chemotherapy-resistant cells (Zitvogel et al., 2008). Parvovirus infec-
tion of tumor cells has also demonstrated the activation of an anti-
tumor immune response in both human tumor lines in vitro and
mouse models in vivo (Bhat et al., 2011; Grekova et al., 2012, 2011;
Raykov et al., 2007). In one of these studies, immunocompetent mice
challenged with MVM-infected glioma were fully protected from
tumor growth, while only 20% of immunodeﬁcient mice demonstrated
protection (Grekova et al., 2012). Therefore, while an expanding
infection may increase the number of tumor cells infected, immuno-
genic death of cells that can only sustain a single round of infection
might still promote the activation of an anti-tumor immune response,
leading to the targeted immune destruction of cells far beyond the
scope of those initially infected.
Parvoviruses could also be used as adjuvants to more conven-
tional therapy, and have demonstrated the potential to target cancer
cells with acquired resistance to chemotherapy. Malignant cells often
up-regulate survival signals that render them unresponsive to the
activation of death pathways triggered by chemotherapy. However,
parvovirus-mediated death can occur via a range of pathways
depending on the virus serotype and host, with caspase-dependent
apoptosis, p53-independent apoptosis, and necrosis all having been
described (Mincberg et al., 2011; Moehler et al., 2001; Ran et al.,
1999; Rayet et al., 1998). For instance, glioma cells resistant to both
TRAIL- and cisplatin-mediated death due to an over-expression of
Bcl-2 family survival signals were successfully killed by H1-mediated
activation of an alternative, cathepsin-mediated death pathway
(Di Piazza et al., 2007).
In conclusion, we found that a chimeric parvovirus, LuCap, can
infect a majority of freshly isolated, patient-derived malignant mela-
noma cell lines, resulting in their death. Current understanding of the
therapeutic importance of the activation of an anti-tumor immune
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such a response, strongly indicates that parvoviral therapy of malig-
nant melanoma merits further study. We suggest that a single round
of infection with ensuing cell death might be sufﬁcient for a
therapeutic response in vivo, particularly if combined with the
delivery of immunomodulatory gene products, or with antibody-
mediated immunotherapy. Further study of the blocks to infection in
both resistant and intermediate cell lines may elucidate strategies for
circumventing them, thus further optimizing infection and therapeutic
efﬁcacy.Materials and methods
Cells
Low-passage, patient-derived melanoma cell lines were pro-
vided by Antonella Bacchiocchi in the Specimen Research Core of
the Yale Specialized Program of Research Excellence (SPORE) in
Skin Cancer, and cultured as described by Tworkoski et al. (2011),
in Opti-MEM (Invitrogen, Grand Island, NY) containing 5% fetal
bovine serum (FBS), and 1% glutamine, penicillin, and streptomy-
cin. The stepwise-transformed melanoma models Mel-STR (Gupta
et al., 2005) and pMel-TCP-BRAF (Garraway et al., 2005) were the
kind gifts of Dr. Robert Weinberg (Whitehead Institute for Biome-
dical Research) and Dr. David Fisher (Harvard Medical School),
respectively. Both cell lines were grown in DMEM containing 10%
fetal bovine serum, and 1% glutamine, penicillin, and streptomycin.
Viruses
All virus stocks were grown in HeLa cells or in NB 324 K cells
(simian virus 40-transformed human newborn kidney cells), and
puriﬁed on step-gradients of iodixanol (Optiprep, Axis-Shield, Oslo,
Norway) as previously described (Cotmore et al., 2010). Titers reﬂect
encapsidated viral genomes, as quantitated by Southern blot follow-
ing micrococcal nuclease digestion and alkaline gel electrophoresis.
The probe used was the oligonucleotide 5′-AACTTTCCATTTAAT-
GACTGTACCAACAA-3′, representing a DNA sequence in the helicase
domain of NS1 that is conserved throughout the rodent parvoviruses,
labeled at its 5′-end with 32P-ATP using polynucleotide kinase, as
described previously (Cotmore and Tattersall, 2005a).
Cell killing assay
Ten thousand cells were seeded overnight in a 1 ml volume per
well in 24-well plates. Viruses were serially diluted 1:5 in growth
medium beginning with a multiplicity of infection (MOI) of 5000
viral genome equivalents (vge) per cell, added as a 500 ml inocu-
lum directly to the medium in each well. After 6 days of incubation
at 37C, the medium was removed, and cells were ﬁxed in
Leishmann′s stain.
Infection initiation assay
Two hundred thousand cells were seeded overnight in 2 ml of
medium per well in a 6-well plate. Virus was diluted to the desired
concentration in growth medium, added in a 500 ml volume
directly to the medium in each well, and incubated at 37 1C. After
24 h of infection, medium was transferred to a collection tube,
cells were harvested by trypsinization, and collected into the
medium. Cells were then pelleted at 400 g for 3 min (the same
parameters were used for all subsequent spins), and ﬁxed in 1%
paraformaldehyde in FACS buffer (1% FBS in PBS) for 30 min at
4 1C, washed once with FACS buffer, and blocked for 30 min in
FACS buffer containing 10% BSA. Cells were stained for NS1 withthe mouse monoclonal antibody CE10B10 (Yeung et al., 1991) in
iFACS buffer (1% FBS, 1% Saponin in PBS) for 1 h at 4 1C, washed
twice with iFACS buffer, then stained for 1 h at 4 1C with Alexa-
Fluor 488-conjugated goat anti-mouse IgG (Invitrogen) secondary
antibody. Stained cells were analyzed on a FACSCalibur ﬂow
cytometer (Becton Dickinson, Franklin Lakes, NJ), using gating
values established with infected cells, prepared as described
above, but without incubation with the primary antibody. Results
are expressed in histogram formwith error bars that represent the
standard deviation of the mean for duplicate infections.
Infection expansion assay
Two hundred thousand cells per well were seeded overnight in
a 6-well plate. Cells were infected with 100 vge/cell as described in
the initiation assay, and collected for staining at 24, 48, and 72 h.
Following tryspinization and ﬁxation, cells were washed twice
with FACS buffer and stored in 200 ml FACS buffer at 4 1C until all
samples were collected. Cells were stained for NS1 as described in
the initiation assay.
Virus internalization assay
One hundred thousand cells per well were seeded overnight in a
24-well plate in 1 ml of medium. “Pre-cleaved” control cells were
pre-incubated for 30 m with 200 ml neuraminidase-supplemented
growth medium, then infected for 4 h with 108 total viral genomes
in neuraminidase-supplemented medium, followed by a 2 h incu-
bation in neuraminidase-supplemented growth medium. To mea-
sure binding and uptake, cells were infected with 108 total genomes
for 4 h, followed by a 2-h incubation in growth medium. To
measure virus occlusion, cells were infected with 108 total genomes
for 4 h, followed by a 2-h incubation in neuraminidase-
supplemented growth medium. All wells were washed twice with
1 ml PBS, and covered with 100 ml of DirectPCR lysis buffer (Viagen,
Los Angeles, CA). Total input virus was measured by adding 108 total
LuCap genomes to the lysis buffer in an uninfected well. The plate
was incubated overnight at 45 1C, and then 85 1C for 45 min. Lysates
were used at a 1:10 dilution in a quantitative TaqMan qPCR assay
for viral genomes Paglino et al., (2007) with the outside primers OK
reverse 5′-CCCATTCCATGTCCTCGC-3′ and OK forward 5′-GCAGGAG
GACGAGCTGAAAT-3′ and the FAM-labeled probe 5′-FAM-TCCCAAG
TAGTTTCCGCTCCTCGTTGTAAA-TAMRA-3′, and analyzed with a
Realplex Mastercycler (Eppendorf, Hauppauge, NY).
Analysis of viral gene transcription
Two hundred thousand cells were seeded overnight in 2 ml of
growth medium per well in a 6-well plate. Growth medium was
replaced with 1 ml of infection medium containing 5000 vge/cell of
LuCap virus for 4 h at 37 1C, and then replaced with 2 ml of
neuraminidase-supplemented growth medium for an additional
20 h. RNA was harvested according to the RNeasy kit (Qiagen, Santa
Clara, CA) with an on-column DNA digestion according to the RNase-
Free DNase Set instructions (Qiagen), and cDNAwas synthesized using
a ProtoScript M-MuLV First Strand cDNA Synthesis Kit (New England
BioLabs, Beverly, MA), from 1.0 μg of total RNA, to yield a ﬁnal volume
of 50 μl. cDNAwas used at a 1:10 dilution in a SYBR Green qPCR assay
(SABiosciences, Frederick, MD). Oligonucleotide primer pairs that bind
exclusively to cDNAs from spliced R1 and R2 transcripts were as
follows: R1 (NS1-encoding) transcripts were ampliﬁed with the
forward primer R1-FOR 5′-CCAACTCCTATAAATTTACTAG-3′ and the
reverse primer SPL-REV 5′-ACCAAGTGATTTCAGGCCTTAG-3′. R2
(NS2-encoding) transcripts were ampliﬁed with the forward primer
R2-SPL-FOR 5′-GATGAAATGACCAAAAAGGTTC-3′ and the reverse
primer SPL-REV.
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Cells were seeded and infected as described for above transcrip-
tion analysis. Cell were lysed and quantiﬁed with a Pierce BCA
Protein Assay Kit (Thermo Scientiﬁc) as previously described (Ruiz
et al., 2011). About 50 mg aliquots (with 100 mM DTT and loading
dye) were loaded in a 4–20% Mini-Protean TGX Gel (Bio-Rad,
Hercules, CA), and transferred to a Hybond ECL membrane (GE
Healthcare). Membranes were blocked, incubated with a rabbit
antibody directed against MVM NS1/2 N-terminal peptide (Cotmore
and Tattersall, 1986) for the non-structural proteins, or the “LUCAPS”
rabbit antibody directed against the capsid gene products VP1 and
VP2 (Paglino and Tattersall, 2011), and developed using an ECL
system according to the manufacturer′s instructions (Amersham,
Uppsala, Sweden).
Analysis of viral DNA replication
Cells were seeded and infected as described for capsid assem-
bly. Cells were collected by trypsinization at 6, 24, and 48 h, and
DNA was extracted from cell pellets as previously described
(D′Abramo et al., 2005). DNA was ﬁrst quantiﬁed by qPCR using
a TaqMan assay as described for the internalization assay. To
distinguish between replicative forms, and single-stranded forms
of DNA in these samples, the DNA was separated by size in a 1.4%
neutral agarose gel by electrophoresis, and detected by Southern
blot analysis as before.
Capsid assembly and genome packaging
Five hundred thousand cells were seeded overnight in 5 ml
growth medium in a 60 mm dish. Cells were infected with 1000
vge/cell in 1 ml of infection medium, and incubated at 37 1C for an
additional 44 h in 5 ml of neuraminidase-supplemented growth
medium. Cells were collected into the medium by scraping,
pelleted at 2000 g for 10 min, resuspended in 120 ml of 50 mM
Tris–HCl, 0.5 mM EDTA, pH 8.7 (TE8.7), then frozen and thawed
three times. Cell debris was pelleted at 2000 g for 10 min, and
100 ml of cleared cell lysate was centrifuged through a small-scale
(1 ml) iodixanol step gradient, as previously described (D′Abramo
et al., 2005) modiﬁed to contain: 96 ml of 55%, 191 ml of 45 and 35%,
and 96 ml of 15% iodixanol. Fractions were collected from the top of
the tube in 50 ml aliquots, with the ﬁnal aliquot being designated
fraction #1. About 5 ml of each fraction was analyzed for capsid
proteins by western blot as described above for the analysis of
viral gene expression. Encapsidated DNA was detected by South-
ern blot following micrococcal nuclease digestion and alkaline gel
electrophoresis as previously described (Farr and Tattersall, 2004).
To measure the release of progeny virions, extracellular medium
was treated with micrococcal nuclease digestion as previously
described (Farr and Tattersall, 2004). Virions were concentrated
from the medium by precipitating overnight at 20 1C in three
volumes of 100% ethanol, pelleting at 14,000 rpm for 30 min,
washing twice with 70% ethanol, and eluting with H2O prior to
running on an alkaline gel. Probed blots were analyzed on a
Typhoon Trio variable-mode imager (GE Healthcare, Piscataway,
NJ) using ImageQuant TL 7.0 image analysis software.
Measurement of virus-induced cell death
Two hundred thousand cells were seeded per well overnight in
2 ml of medium in a 6-well plate. Growth mediumwas replaced with
1 ml of infection medium (Opti-MEM supplemented with 1% FBS and
20 mMHEPES, pH 7.3) containing 1000 vge/cell of LuCap virus for 4 h
at 37 1C. Inoculum was then removed and replaced with 2 ml of
neuraminidase-supplemented (0.1 g/ml) growth medium for theremainder of the experiment to restrict the infection to a single
round. Cells and mediumwere collected as described in the initiation
assay, and washed once with 1 ml PBS. Cells were stained with the
far red LIVE/DEAD Fixable Dead Cell Kit (Invitrogen) and ﬁxed
according to the manufacturer′s instructions. Cells were resuspended
in FACS buffer and stored at 4 1C until all time points had been
collected (24, 48 and 72 h), then stained for NS1 as described in the
initiation assay, and analyzed by ﬂow cytometry.Acknowledgments
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